Acute Myocardial Infarct
Obstruction of the coronary blood flow during myocardial infarct limits oxygen supply to the heart. This promotes cardiac ischemia, cardiac dysfunction and ischemic heart disease. Ischemic heart disease feeds into a cardiometabolic disease acceleration loop.
- Fast therapeutic intervention to reperfuse tissue is essential for survival and positive prognosis
- No pharmacological option for the rescue of heart function currently exists
- There are more than 3 mio cases of AMI annually (1 mio in US only) and the estimated out of hospital mortality is 30-50%.
- Currently, patients reaching the hospital for acute surgery foresee 10% mortality risk, 35% risk of secondary heart failure and 5-10% risk of 30-days readmission.
The Epoqe Pharma Concept
Our PP compounds are analogs of a native peptide. PPs induce > 85% heart function recovery, > 55% perfusion defect recovery and increased survival rate in pre-clinical proof-of-concept studies in minipig (ischemia and rerperfusion) and rat (ischemia and reperfusion).
The compounds have highly conserved biological actions among species. The solid rationale is based on well established biology, a well characterized receptor population and preferred actions, specifically in the heart tissue.
Clinical expectations of PPs
We expect PPs to be safe based on long term clinical studies with the native peptide.
Based on non-clinical studies we expect PPs to reduce the AMI patient mortality rate, reduce hospitalization, improve heart function and quality of life and reduce the risk of developing secondary heart failure
Importantly, the clinical efficacy is expected to be independent on the well established risk factors leading to the heart attack (e.g. age, diabetes, hypertension, dyslipideamia and coagulant status).
THE TEAM
